Monograph Details
|
|
Respiratory Tract
> Oropharyngeal conditions
|
|
SALAGEN |
| Manufacturer |
|
MGI Pharma, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Cholinergic. |
| Generic Name |
|
Pilocarpine (as HCl) 5mg, 7.5mg; tabs. |
| Indications |
|
Dry mouth (xerostomia) due to radiotherapy for head and neck cancer or Sjogren's syndrome. |
| Children |
|
Not recommended. |
| Adults |
|
Cancer: Initially 5mg three times daily; range 15–30mg daily; max 10mg/dose. Sjogren's syndrome: 5mg four times daily. Moderate hepatic impairment for both: 5mg twice daily. |
| Contraindications |
|
Uncontrolled asthma. When miosis is undesirable (iritis, narrow-angle glaucoma). |
| Precautions |
|
Severe hepatic impairment: not recommended. Cardiovascular disease. Controlled asthma. Chronic bronchitis. COPD. Cholethiasis. Biliary tract disease. Nephrolithiasis. Cognitive or psychiatric disorders. Activities requiring visual acuity. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Cardiac conduction disturbances with β-blockers. Potentiates parasympathomimetics. Antagonizes anticholinergics (eg, atropine, ipratropium). |
| Adverse Reactions |
|
Sweating, nausea, rhinitis, chills, flushing, urinary frequency, dizziness, asthenia, headache, abnormal vision. |
| How Supplied |
|
Tabs—100 |
|
|
|
|
